Johnson & Johnson vs Stripe
Side-by-side comparison of AI visibility scores, market position, and capabilities
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
Global payments infrastructure founded by Patrick and John Collison (YC W10); $1.4T payments volume in 2024; $18B+ revenue; $106.7B valuation as of Sept 2025; powers everything from startups to Fortune 500 companies with developer-first API design.
About
Stripe is a global payments infrastructure company founded in 2010 by Irish brothers Patrick and John Collison, headquartered in San Francisco, California and Dublin, Ireland. Stripe was born from the insight that accepting payments online was unnecessarily complex for developers, and that a well-designed API could unlock an entire generation of internet businesses. The company went through Y Combinator's Winter 2010 batch and grew to become the defining payments infrastructure layer of the modern internet economy, processing payments for businesses in virtually every industry worldwide.\n\nStripe's platform provides payment processing, fraud prevention via Stripe Radar, subscription billing, revenue recognition, banking-as-a-service through Stripe Treasury, corporate card issuance, identity verification, and tax compliance tools. It serves a spectrum from early-stage startups to publicly traded enterprises including Amazon, Google, Salesforce, and Shopify. Stripe's developer-first philosophy — comprehensive documentation, SDKs in every major language, and a sandbox testing environment — created an ecosystem of millions of businesses built entirely on its infrastructure.\n\nStripe processed $1.4 trillion in total payment volume in 2024 and generates over $18 billion in annual revenue, with a valuation of $106.7 billion as of September 2025. The company has remained private longer than most comparably sized technology companies, giving it flexibility to invest in long-term product expansion. An April 2024 partnership with Apple Pay extended Stripe's reach further into mobile and in-store commerce. Stripe competes with Adyen, Braintree (PayPal), and Square, but its developer ecosystem depth and global infrastructure make it the default payments platform for a generation of technology companies.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.